David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Andrew D. Zelenetz, MD, PhD, and Stephan Stilgenbauer, MD, PhD on CLL and Venetoclax: Clinical Trial Results

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Stephan Stilgenbauer, MD, PhD, of the University of Ulm, discuss this late-breaking abstract on venetoclax monotherapy and deep remissions in ultra-high risk relapsed/refractory chronic lymphocytic leukemia with 17p deletion (Abstract LBA6).

Leukemia

Hagop M. Kantarjian, MD

Hagop M. Kantarjian, MD, on AML: Safety and Efficacy of Guadecitabine

Hagop M. Kantarjian, MD, of MD Anderson Cancer Center, discusses a study that compared efficacy and safety results of using 5-day and 10-day regimens of a novel hypomethylating agent in 103 treatment-naïve AML patients who were not candidates for intensive chemotherapy (Abstract 458).

Lymphoma

Kieron Dunleavy, MD

Kieron Dunleavy, MD, on Burkitt Lymphoma: Preliminary Report of the DA-EPOCH-R Trial

Kieron Dunleavy, MD, of the National Cancer Institute, discusses a multi-center trial that set out to validate the effectiveness of DA-EPOCH-R-based therapy and whether a risk-adapted approach using the regimen is beneficial for patients with Burkitt lymphoma (Abstract 342).

David A. Williams, MD

David A. Williams, MD, on the Goals and Highlights of ASH 2015

Outgoing ASH President, David A. Williams, MD, of the Dana-Farber/Boston Children’s Hospital, gives an overview of this year’s Annual Meeting of the American Society of Hematology.

Multiple Myeloma

James N. Kochenderfer, MD

James N. Kochenderfer, MD, on Multiple Myeloma: Results of a First-in-Humans Clinical Trial

James N. Kochenderfer, MD, of the National Cancer Institute, reports on remissions of multiple myeloma during a trial of T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor (Abstract 99).

Oct

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Andrew D. Zelenetz, MD, PhD, and Stephan Stilgenbauer, MD, PhD on CLL and Venetoclax: Clinical Trial Results

Hagop M. Kantarjian, MD, on AML: Safety and Efficacy of Guadecitabine

Kieron Dunleavy, MD, on Burkitt Lymphoma: Preliminary Report of the DA-EPOCH-R Trial

David A. Williams, MD, on the Goals and Highlights of ASH 2015

James N. Kochenderfer, MD, on Multiple Myeloma: Results of a First-in-Humans Clinical Trial

FDA Approves Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer

National Academy of Medicine Elects 100 New Members for 2026

Phase III VERIFY Trial Demonstrates Benefits of Rusfertide in Polycythemia Vera

ASH Issues New Recommendations for the Management of Myelofibrosis

Immunotherapy-Based Downstaging Linked to Improved Outcomes After Liver Transplantation in Hepatocellular Carcinoma